RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
This Quarter Return
+21.75%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$3.87B
AUM Growth
+$3.87B
(+13%)
Cap. Flow
+$152M
Cap. Flow
% of AUM
3.92%
Top 10 Holdings %
Top 10 Hldgs %
35.18%
Holding
134
New
3
Increased
60
Reduced
11
Closed
5
Top Buys
| 1 |
Immunocore
IMCR
|
$38.6M |
| 2 |
BPMC
Blueprint Medicines
BPMC
|
$36.8M |
| 3 |
Akero Therapeutics
AKRO
|
$23.5M |
| 4 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
$20.7M |
| 5 |
Gossamer Bio
GOSS
|
$19M |
Top Sells
Sector Composition
| 1 | Healthcare | 96.8% |
| 2 | Consumer Staples | 0.91% |
| 3 | Industrials | 0.67% |
| 4 | Financials | 0.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Humana
HUM
$36.5B
| $207M | 5.35% | 426,500 +142 | +0% | +$68.9K |
|
2
Agilon Health
AGL
$530M
| $181M | 4.69% | 7,747,500 +66,500 | +0.9% | +$1.56M |
|
|
3
Immunocore
IMCR
$1.62B
| $164M | 4.24% | 3,493,743 +822,091 | +31% | +$38.6M |
|
4
UnitedHealth
UNH
$281B
| $136M | 3.52% | 269,500 +1,000 | +0.4% | +$505K |
|
5
argenx
ARGX
$43.6B
| $124M | 3.19% | 350,000 | – | – |
|
6
Neurocrine Biosciences
NBIX
$13.8B
| $119M | 3.08% | 1,122,500 | – | – |
|
7
Insulet
PODD
$23.9B
| $119M | 3.07% | 518,500 +16,500 | +3% | +$3.79M |
|
8
Evolent Health
EVH
$1.12B
| $117M | 3.03% | 3,262,500 +524,500 | +19% | +$18.8M |
|
|
BPMC
9
DELISTED
Blueprint Medicines
BPMC
| $101M | 2.62% | 1,538,195 +559,021 | +57% | +$36.8M |
|
|
KRTX
10
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $93.1M | 2.4% | 413,762 -28,131 | -6% | -$6.33M |
|
11
Penumbra
PEN
$10.6B
| $90.3M | 2.33% | 476,000 +74,500 | +19% | +$14.1M |
|
12
Agios Pharmaceuticals
AGIO
$2.19B
| $86.5M | 2.23% | 3,057,869 +129,411 | +4% | +$3.66M |
|
13
Idexx Laboratories
IDXX
$51.8B
| $73.1M | 1.89% | 224,315 +565 | +0.3% | +$184K |
|
14
Align Technology
ALGN
$10.3B
| $71.2M | 1.84% | 344,000 -10,500 | -3% | -$2.17M |
|
|
CERE
15
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $70.6M | 1.82% | 2,499,148 +732,007 | +41% | +$20.7M |
|
16
Alnylam Pharmaceuticals
ALNY
$58.5B
| $66.6M | 1.72% | 332,500 | – | – |
|
17
Acadia Healthcare
ACHC
$2.12B
| $66.1M | 1.71% | 845,000 +91,500 | +12% | +$7.15M |
|
18
Aclaris Therapeutics
ACRS
$209M
| $62.4M | 1.61% | 3,961,249 +34,100 | +0.9% | +$537K |
|
|
MRTX
19
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $60.5M | 1.56% | 866,776 +21,799 | +3% | +$1.52M |
|
20
Intuitive Surgical
ISRG
$170B
| $56M | 1.45% | 298,500 | – | – |
|
21
Pacira BioSciences
PCRX
$1.2B
| $54.1M | 1.4% | 1,017,500 | – | – |
|
22
Edwards Lifesciences
EW
$47.8B
| $52.1M | 1.35% | 631,000 +29,000 | +5% | +$2.4M |
|
|
SWAV
23
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
| $50.1M | 1.29% | 180,100 -60,400 | -25% | -$16.8M |
|
24
Ultragenyx Pharmaceutical
RARE
$2.89B
| $49.2M | 1.27% | 1,187,992 +94,962 | +9% | +$3.93M |
|
25
Sarepta Therapeutics
SRPT
$1.78B
| $47.5M | 1.23% | 430,000 +2,000 | +0.5% | +$221K |
|